Investigation on the complementation significance of combined cTnI，IMA and hs-CRP determination in coronary heart disease

Abstract

Abstract: Objective　To investigate the application and clinical significance of combined determination of cardiac troponin I（cTnI），ischemia modified albumin（IMA） and high sensitive C reactive protein（hs-CRP） in coronary heart disease. Methods　Enzyme-linked immunosorbent assay (ELISA) kits from the same company were used to measure the all markers. According to the measured results of cTnI were higher or not than the reference value (0.173ng/mL), 142 patients were classified into 2 groups ［cTnI non-increasing (<0.173 ng/mL) group: 91 cases, cTnI increasing (≥0.173 ng/mL) group: 51 cases］. A total of 78 healthy subjects were enrolled as controls. The combined determination of cTnI, IMA and hs-CRP was performed. Results　Among coronary heart disease patients in cTnI non-increasing group, their IMA and hs-CRP levels increased slightly compared with those in the control group（P<0.05）. The IMA and hs-CRP levels among coronary heart disease patients in cTnI increasing group increased significantly（P<0.01）. Among coronary heart disease paritents in cTnI non-increasing group, the IMA levels of 27 patients (30%) increased slightly, and the hs-CRP levels of 34 patients (37%) increased. Conclusions　The combined determination of cTnI，IMA and hs-CRP has complementation significance in diagnosis of myocardial ischemia and myocardial injury.

Key words: Cardiac troponin I, Ischemia modified albumin, High sensitive C reactive protein, Coronary heart disease

WU Weihua;YI Jianhua. Investigation on the complementation significance of combined cTnI，IMA and hs-CRP determination in coronary heart disease[J]. , 2012, 27(5): 361-363.

References

［1］靳彩宁，徐国宾，朱立华，等. 人心肌TnI的生物学特性测定及其在临床诊断中的应用［J］. 临床检验杂志，2002，20（2）：118-120.
［2］Dawie J，Chawla R，Worku Y，et al. Diagnosis of ischemic heart disease using CK-MB， troponin-I and ischemia modified albumin［J］. Ethiop Med J，2011，49（1）：25-33.
［3］Sinha MK，Roy D，Gaze DC，et al. Role of "ischemia modified albumin"，a new biochemical marker of myocardial ischaemia，in the early diagnosis of acute coronary syndromes［J］. Emerg Med J，2004，21（1）：29-34.
［4］Collinson PO，Gaze DC，Bainbridge K，et al. Utility of admission cardiac troponin and "ischemia modified albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department［J］. Emerg Med J，2006，23（4）：256-261.
［5］Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk： moving an inflammatory hypothesis toward consensus［J］. J Am Coll Cardiol，2007，49（21）：2129-2138.
［6］Rifai N，Ridker PM. High-sensitivity C-reactive protein： a novel and promising marker of coronary heart disease［J］. Clin Chem，2001，47（3）：403-411.
［7］Keller T，Zeller T，Peetz D，et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction［J］. N Engl J Med，2009，361（9）：868-877.
［8］Collinson PD，Gaze DC. Ischaemia-modified albumin：clinical utility and pitfalls in measurement［J］. J Clin Pathol，2008，61（9）：1025-1028.
［9］Manini AF，Ilgen J，Noble VE，et al. Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain［J］. Emerg Med J，2009，26（11）：791-796.
［10］Schiele F，Meneveau N，Seronde MF，et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes［J］. Eur Heart J，2010， 31（3）：290-297.

[1]	MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664.
[2]	WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589.
[3]	MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168.
[4]	LIU Jinyan, ZHAO Juntao, XIANG Mingjie. Mechanism and application of serum amyloid A in clinical diseases [J]. Laboratory Medicine, 2021, 36(7): 756-760.
[5]	WANG Linlin, FAN Jun, YE Chenyu, YING Chunmei. Correlation between blood lipid and carotid atherosclerotic plaque in elderly patients with coronary heart disease [J]. Laboratory Medicine, 2021, 36(6): 618-622.
[6]	ZHANG Xilin, SHEN Yifeng, ZHU Jing, ZHANG Chunyan, SHAO Wenqi, WANG Beili, GUO Wei. Roles of AST,m-AST and m-AST/AST in preoperative and postoperative evaluation of patients with CHD and AMI [J]. Laboratory Medicine, 2021, 36(5): 471-476.
[7]	HE Chengshan, YAO Xiaoyang, JIANG Xiudi, LU Zhicheng. Microarray chemiluminescence immunoassay for quantitative detection of cardiac troponin I autoantibodies and preliminary clinical applications [J]. Laboratory Medicine, 2021, 36(3): 318-324.
[8]	WANG Beili, LI Huijun, WU Yan’an, DAI Wanru, LI Yihao, GUO Wei, PAN Baishen. Correlation between serum biochemical parameters and the degree of coronary artery stenosis in patients with coronary heart disease [J]. Laboratory Medicine, 2020, 35(1): 6-10.
[9]	SHU Ming, JIN Lu, CHEN Qiuying. Role of serum hepcidin in the diagnosis of myocardial damage among coronary heart disease patients [J]. Laboratory Medicine, 2019, 34(9): 783-786.
[10]	TONG Minghong, DING Hui, JIANG Yinting, SUN Hanxiao, XUAN Binbin, SHENG Huiming. Role of the determination of statin metabolism-related gene in the treatment of cardiovascular and cerebrovascular diseases [J]. Laboratory Medicine, 2019, 34(6): 491-497.
[11]	DING Ning, CHEN Changqiang, FAN Qishi. Correlations of RDW and TB with coronary heart disease and the extent of coronary atherosclerosis [J]. Laboratory Medicine, 2019, 34(10): 889-893.
[12]	YANG Xuesong, SUN Fenyong, LI Zebing, WANG Jian. Roles of nitric oxide,endothelin-1 and homocysteine for the auxiliary diagnosis of coronary heart disease [J]. Laboratory Medicine, 2018, 33(4): 316-320.
[13]	ZHANG Shaohong, SHEN Xuebin. CYP2C19 gene polymorphism in the drug therapy of coronary heart disease [J]. Laboratory Medicine, 2018, 33(11): 979-982.
[14]	ZHENG Jianxin, YANG Hui, FU Qihua. Establishment of pediatric reference interval of cTnI in Shanghai based on rapid immunochromatography [J]. Laboratory Medicine, 2018, 33(10): 875-878.
[15]	YANG Yan, ZHANG Fujun, SHEN Songkun, WANG Houzhao. NT-proBNP,cTnI,Hcy,DD and hs-CRP for the diagnosis of coronary heart disease by ROC curves [J]. Laboratory Medicine, 2018, 33(1): 15-19.